AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11906418 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltrated groin
Number of subjects: 18
Study 11906418 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-incision infiltration
Number of subjects: 18
Study 10023943 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 1.25 mg daily, increased to a maximum of 10 mg per day
Number of subjects: 2647
Study 10023943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2647
Study 7844685 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 104
Study 7844685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 2110430 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and hydroxychloroquine (n = 11)
Number of subjects: 38
Study 2110430 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide and hydroxychloroquine (n = 8)
Number of subjects: 38
Study 2110430 — intervention group
Group type: COMPARATOR
Intervention: Insulin and placebo (n = 11)
Number of subjects: 38
Study 2110430 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide and placebo (n = 8)
Number of subjects: 38
Study 681529 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making and self-management program
Number of subjects: 0
Study 681529 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 31924567 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal breech birth
Number of subjects: 0
Study 31924567 — intervention group
Group type: COMPARATOR
Intervention: Planned caesarean birth
Number of subjects: 0
Study 31542451 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air inhalation
Number of subjects: 30
Study 31542451 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline inhalation
Number of subjects: 30
Study 27856801 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) 40 mg
Number of subjects: 40
Study 27856801 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone acetate (MA) 40 mg
Number of subjects: 40
Study 25890808 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA implant
Number of subjects: 61
Study 25890808 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing TKA implant
Number of subjects: 61
Study 23376864 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil, 50 to 100 mg as needed
Number of subjects: 102
Study 21795740 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrogenated soybean oil (15.7 g/day IP‐TFA)
Number of subjects: 52
Study 21795740 — intervention group
Group type: COMPARATOR
Intervention: Control oil without IP‐TFA
Number of subjects: 52
Study 19750794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand workstation paradigm
Number of subjects: 60
Study 18003511 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ng/ml effect compartment controlled remifentanil
Number of subjects: 45
Study 18003511 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ng/ml effect compartment controlled remifentanil
Number of subjects: 45
Study 18003511 — intervention group
Group type: COMPARATOR
Intervention: No remifentanil
Number of subjects: 45
Study 15003429 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram for up to 12 weeks
Number of subjects: 24
Study 11465304 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered discontinuation of cyclosporin microemulsion
Number of subjects: 0
Study 11465304 — intervention group
Group type: COMPARATOR
Intervention: Abrupt discontinuation of cyclosporin microemulsion
Number of subjects: 0
Study 9479803 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1481786 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Bereavement Program
Number of subjects: 0
Study 1481786 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 4063085 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor therapy exercises with elements of games (B2 subgroup)
Number of subjects: 180
Study 4063085 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor therapy exercises with 5.2 mg of nitrong 1 hour prior to PT (B3 subgroup)
Number of subjects: 180
Study 4063085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometry with stable load of 50% of individual exercise tolerance (B4 subgroup)
Number of subjects: 180
Study 4063085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometry with stable load of 75% of individual exercise tolerance (B5 subgroup)
Number of subjects: 180
Study 4063085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometry with gradually increased load (50-75-90% of individual exercise tolerance) (B6 subgroup)
Number of subjects: 180
Study 31082285 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 108
Study 31082285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT)
Number of subjects: 108
Study 31082285 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 108
Study 31082285 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 108
Study 29195836 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to monotherapy from two non‐clozapine oral antipsychotics
Number of subjects: 90
Study 29195836 — intervention group
Group type: COMPARATOR
Intervention: Stay on polypharmacy with two non‐clozapine oral antipsychotics
Number of subjects: 90
Study 29195836 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to monotherapy from combinations involving clozapine or an injectable antipsychotic
Number of subjects: 90
Study 29195836 — intervention group
Group type: COMPARATOR
Intervention: Stay on polypharmacy with combinations involving clozapine or an injectable antipsychotic
Number of subjects: 90
Study 27339838 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb scaffold
Number of subjects: 445
Study 27339838 — intervention group
Group type: COMPARATOR
Intervention: Xience stent
Number of subjects: 445
Study 24752130 — intervention group
Group type: EXPERIMENTAL
Intervention: LEEP
Number of subjects: 244
Study 24752130 — intervention group
Group type: COMPARATOR
Intervention: CKC
Number of subjects: 244
Study 21725935 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.02%) applied on surgical flaps (group A)
Number of subjects: 88
Study 21725935 — intervention group
Group type: COMPARATOR
Intervention: Control group without mitomycin C application (group B)
Number of subjects: 88
Study 19615296 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIPPV)
Number of subjects: 1069
Study 19615296 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 1069
Study 19615296 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 1069
Study 19615296 — intervention group
Group type: COMPARATOR
Intervention: Economic evaluation
Number of subjects: 1069
Study 17627166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g (first-generation cephalosporin)
Number of subjects: 0
Study 17627166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg (second-generation cephalosporin)
Number of subjects: 0
Study 17627166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 1 g (third-generation cephalosporin)
Number of subjects: 0
Study 17627166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15333087 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-activated transtelephonic event recorder for 30 days, mean of 642 +/- 195 days after ablation
Number of subjects: 244
Study 15333087 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-activated transtelephonic event recorder for 30 days
Number of subjects: 244
Study 11575619 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Distortion (PD) group (n=76)
Number of subjects: 192
Study 11575619 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Distortion (ND) group (n=79)
Number of subjects: 192
Study 11575619 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=37)
Number of subjects: 192
Study 11575619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoff scores suggested for classification accuracy
Number of subjects: 192
Study 11575619 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare Virtues and Deviance
Number of subjects: 192
Study 9696497 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon inflation technique
Number of subjects: 20
Study 9696497 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon deflation technique
Number of subjects: 20
Study 9696497 — intervention group
Group type: COMPARATOR
Intervention: Portal pressure measurement
Number of subjects: 20
Study 9696497 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term TIPS occlusion
Number of subjects: 20
Study 8998252 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3.3 mg/kg, equivalent to 2 to 3 cups of coffee)
Number of subjects: 32
Study 8998252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8998252 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 32
Study 2233278 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg nandrolone decanoate as an intramuscular depot every third week for 1 year
Number of subjects: 79
Study 2233278 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17 beta‐estradiol plus 1 mg norethisterone acetate daily for 1 year
Number of subjects: 79
Study 2233278 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections every third week for 1 year
Number of subjects: 79
Study 2233278 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets for 1 year
Number of subjects: 79
Study 630919 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a polyester fiber sponge to remove scales from lesions on the left side
Number of subjects: 20
Study 630919 — intervention group
Group type: COMPARATOR
Intervention: Control side (no sponge used)
Number of subjects: 20
Study 31989150 — intervention group
Group type: EXPERIMENTAL
Intervention: French fries prepared from frozen par-fried potatoes
Number of subjects: 31
Study 31989150 — intervention group
Group type: EXPERIMENTAL
Intervention: French fries prepared from fresh potatoes
Number of subjects: 31
Study 31989150 — intervention group
Group type: EXPERIMENTAL
Intervention: French fries with different toasting colors
Number of subjects: 31
Study 31989150 — intervention group
Group type: EXPERIMENTAL
Intervention: All samples that were golden and light-golden
Number of subjects: 31
Study 31989150 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational initiatives for food operators
Number of subjects: 31
Study 30859964 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (DTB) 12mg/day titrating up to 48mg/day
Number of subjects: 0
Study 30859964 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study 30859964 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (DTB)
Number of subjects: 0
Study 28566529 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional cash transfer during the lean season
Number of subjects: 322
Study 28566529 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 322
Study 25040690 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibroblast cell culture (AFCC) on a collagen scaffold under a coronally advanced flap (CAF)
Number of subjects: 18
Study 25040690 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (CTG) with coronally advanced flap (CAF)
Number of subjects: 18
Study 25040690 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AFCC and CTG
Number of subjects: 18
Study 23425163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (150 mg twice daily)
Number of subjects: 2866
Study 23425163 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (active control)
Number of subjects: 2866
Study 23425163 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 2866
Study 21443601 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin 30 mg and ketoconazole 200 mg
Number of subjects: 54
Study 21443601 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin 30 mg and simvastatin 40 mg
Number of subjects: 54
Study 21443601 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin 30 mg and ciclosporin A 300 mg
Number of subjects: 54
Study 21443601 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin 30 mg
Number of subjects: 54
Study 19347367 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplements (10 mg/day)
Number of subjects: 81
Study 19347367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 19347367 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplements (10 mg/day) in frequent relapsers
Number of subjects: 81
Study 16762760 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional midwall ejection fraction (3DEF(mw))
Number of subjects: 49
Study 16762760 — intervention group
Group type: EXPERIMENTAL
Intervention: midwall fractional shortening (FS(mw))
Number of subjects: 49
Study 16762760 — intervention group
Group type: EXPERIMENTAL
Intervention: mitral annular motion (MAM)
Number of subjects: 49
Study 16762760 — intervention group
Group type: COMPARATOR
Intervention: endocardial ejection fraction (EF(endo))
Number of subjects: 49
Study 16762760 — intervention group
Group type: COMPARATOR
Intervention: endocardial fractional shortening (FS)
Number of subjects: 49
Study 16762760 — intervention group
Group type: COMPARATOR
Intervention: 3D endocardial ejection fraction (3D EF(endo))
Number of subjects: 49
Study 16762760 — intervention group
Group type: COMPARATOR
Intervention: systolic tissue velocity
Number of subjects: 49
Study 15504127 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg b.i.d. (single-day oral treatment)
Number of subjects: 52
Study 11825311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine (2 mg b.i.d.)
Number of subjects: 0
Study 11825311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine (4 mg ER capsule, once daily)
Number of subjects: 0
Study 9419912 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaleidoscope distraction intervention
Number of subjects: 96
Study 9419912 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 96
Study 8310986 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA-type diet (32/10:8:8) for 6 months
Number of subjects: 160
Study 8310986 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoene-enriched diet (34/11:11:5) for 6 months
Number of subjects: 160
Study 8310986 — intervention group
Group type: COMPARATOR
Intervention: High-saturated diet (35/14:10:4) for 6 months
Number of subjects: 160
Study 8310986 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (30/12:8:3) for 6 months
Number of subjects: 160
Study 3355578 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms Se as sodium selenite
Number of subjects: 3
Study 3355578 — intervention group
Group type: EXPERIMENTAL
Intervention: 170 mg alpha‐tocopherol
Number of subjects: 3
Study 3355578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 31524734 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic suture repair with additional pronator quadratus (PQ) advancement (46 patients)
Number of subjects: 80
Study 31524734 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic suture repair alone (34 patients)
Number of subjects: 80
Study 28223015 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric device
Number of subjects: 19
Study 28223015 — intervention group
Group type: COMPARATOR
Intervention: Traditional rotary bur
Number of subjects: 19
Study 28223015 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 25381995 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycium barbarum polysaccharide (LBP) at 300 mg/day
Number of subjects: 67
Study 25381995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 67
Study 25381995 — intervention group
Group type: EXPERIMENTAL
Intervention: LBP
Number of subjects: 67
Study 23608698 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast before exercise
Number of subjects: 12
Study 23608698 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting before exercise
Number of subjects: 12
Study 23608698 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast at rest
Number of subjects: 12
Study 23608698 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting before rest
Number of subjects: 12
Study 23608698 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast before rest
Number of subjects: 12
Study 23608698 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast omission
Number of subjects: 12
Study 21672223 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based cluster randomised controlled trials
Number of subjects: 5
Study 21672223 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation exercise
Number of subjects: 5
Study 21672223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster size and number of clusters
Number of subjects: 5
Study 19568710 — intervention group
Group type: EXPERIMENTAL
Intervention: Danggui Buxue Decoction No.1 (DB1)
Number of subjects: 82
Study 19568710 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 82
Study 16948779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation containing melatonin, l‐tryptophan, vitamin B6, folic acid, vitamin B12, methionine and betaine for 40 days.
Number of subjects: 351
Study 16948779 — intervention group
Group type: COMPARATOR
Intervention: 20 mg omeprazole for 40 days.
Number of subjects: 351
Study 15381867 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc ethyl cysteinate dimer SPECT with PVE correction
Number of subjects: 40
Study 11527484 — intervention group
Group type: EXPERIMENTAL
Intervention: Four verbal prompts to drink per day for 16 weeks
Number of subjects: 63
Study 11527484 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight verbal prompts per day for 8 weeks
Number of subjects: 63
Study 11527484 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight verbal prompts per day for 8 weeks plus compliance with beverage preferences
Number of subjects: 63
Study 11527484 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 63
Study 9249120 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 175
Study 9249120 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide 10 mg
Number of subjects: 175
Study 9249120 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 175
Study 8499196 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 0
Study 8499196 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ring anaesthesia (SRA)
Number of subjects: 0
Study 8499196 — intervention group
Group type: COMPARATOR
Intervention: Single cuff (control)
Number of subjects: 0
Study 8499196 — intervention group
Group type: EXPERIMENTAL
Intervention: Double cuff technique
Number of subjects: 0
Study 3092968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 12
Study 3092968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29473704 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QW + IG
Number of subjects: 464
Study 29473704 — intervention group
Group type: COMPARATOR
Intervention: Placebo + IG
Number of subjects: 464
Study 27557407 — intervention group
Group type: EXPERIMENTAL
Intervention: 5°C cold-water immersion
Number of subjects: 42
Study 27557407 — intervention group
Group type: EXPERIMENTAL
Intervention: 15°C cold-water immersion
Number of subjects: 42
Study 27557407 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 24172641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoultrasound therapy
Number of subjects: 102
Study 24172641 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 102
Study 25470572 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride extended-release (MPH-MLR) 15 mg daily
Number of subjects: 20
Study 25470572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25470572 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride extended-release (MPH-MLR)
Number of subjects: 20
Study 21847649 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 499
Study 21847649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 499
Study 18296966 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ballistic and heavy resistance training (COM)
Number of subjects: 17
Study 18296966 — intervention group
Group type: COMPARATOR
Intervention: Heavy resistance training (HR)
Number of subjects: 17
Study 16804432 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine (one of 3 consistency lots)
Number of subjects: 3928
Study 16804432 — intervention group
Group type: COMPARATOR
Intervention: MMR + V (administered at separate injection sites)
Number of subjects: 3928
Study 16804432 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine
Number of subjects: 3928
Study 14530872 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microk/kg PEG‐rHuMGDF as a single dose on day ‐6 (n=37)
Number of subjects: 90
Study 14530872 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microk/kg PEG‐rHuMGDF administered on day ‐6 followed by 10 microg/kg on days ‐5 to day 6 (n=35)
Number of subjects: 90
Study 14530872 — intervention group
Group type: COMPARATOR
Intervention: Placebo as a single dose on day ‐6 (n=9)
Number of subjects: 90
Study 14530872 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered on day ‐6 to day 6 (n=9)
Number of subjects: 90
Study 14530872 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF day ‐6 to 6 group
Number of subjects: 90
Study 11030677 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine speech and language therapy
Number of subjects: 159
Study 11030677 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 159
Study 8865710 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2% hypertonic saline (HS)
Number of subjects: 24